

# Alan Menter

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6852112/alan-menter-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197  
papers

16,548  
citations

57  
h-index

128  
g-index

208  
ext. papers

18,850  
ext. citations

5.7  
avg, IF

6.28  
L-index

#	Paper	IF	Citations
197	Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. <i>Nature Genetics</i> , <b>2009</b> , 41, 199-204	36.3	1038
196	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 826-50	4.5	958
195	Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1181-9	59.2	755
194	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 106-15	4.5	685
193	Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 118-28	59.2	675
192	European S3-guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2009</b> , 23 Suppl 2, 1-70	4.6	586
191	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , <b>2015</b> , 386, 541-549	40	576
190	The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. <i>Archives of Dermatology</i> , <b>2001</b> , 137, 280-4		564
189	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1318-28	59.2	530
188	Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet, The</i> , <b>2009</b> , 373, 633-40	40	476
187	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 534-42	4.5	464
186	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 61, 451-85	4.5	427
185	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 56, 31.e1-15	4.5	370
184	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 851-64	4.5	349
183	Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 643-59	4.5	344
182	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 137-74	4.5	343
181	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1551-1560	59.2	306

180	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1029-1072	4.5	296
179	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 114-135	4.5	267
178	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 155-172	11.5	246
177	Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. <i>British Journal of Dermatology</i> , <b>2007</b> , 157, 649-55	4	236
176	Current and future management of psoriasis. <i>Lancet, The</i> , <b>2007</b> , 370, 272-284	4.0	235
175	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 668-77	4	233
174	A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, 859-66	4.5	205
173	Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 864-71	27.4	202
172	Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 31-8		188
171	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 116-124.e7	11.5	182
170	Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 1148-58	4.6	162
169	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1073-1113	4.5	145
168	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 594-603	4.5	143
167	Biological therapies in the systemic management of psoriasis: International Consensus Conference. <i>British Journal of Dermatology</i> , <b>2004</b> , 151 Suppl 69, 3-17	4	139
166	The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 812-8	4.5	121
165	Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 448-56	4.5	115
164	The use of cyclosporine in dermatology: part I. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 925-46; quiz 947-8	4.5	110
163	Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 274-85	4	109

162	Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 954-60	4	107
161	A subset of methylated CpG sites differentiate psoriatic from normal skin. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 583-92	4.3	104
160	Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 978-83	4.5	103
159	Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. <i>Dermatology</i> , <b>2008</b> , 216, 260-70	4.4	97
158	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. <i>Dermatology and Therapy</i> , <b>2016</b> , 6, 1-12	4	92
157	AAD consensus statement on psoriasis therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 49, 897-9	4.5	91
156	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 137-47	4	89
155	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 1183-1190.e3	4.5	88
154	Burden of disease: psoriasis and psoriatic arthritis. <i>American Journal of Clinical Dermatology</i> , <b>2013</b> , 14, 377-88	7.1	86
153	Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 146-67	4.5	85
152	Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , <b>2018</b> , 9, 5-21	4.9	83
151	Comorbidities in psoriasis patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2010</b> , 29, 10-5	1.4	83
150	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , <b>2018</b> , 11, e007394	3.9	81
149	Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 1024-31	4.5	80
148	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1445-1486	4.5	79
147	The use of cyclosporine in dermatology: part II. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 949-72; quiz 973-4	4.5	72
146	Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2007</b> , 18, 341-50	2.8	72
145	Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 704-10	4	65

144	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 161-201	4.5	63
143	Central obesity and high blood pressure in pediatric patients with atopic dermatitis. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 144-52	5.1	61
142	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 844-852	4	59
141	IL-4R $\beta$ Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 191-202.e7	4.3	57
140	Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 1763-70	4.6	54
139	Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. <i>Journal of Drugs in Dermatology</i> , <b>2014</b> , 13, 1441-8	2.2	52
138	OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 115-22	4.5	51
137	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 70-80	4.5	51
136	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 410-9.e6	4.5	49
135	A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2016</b> , 27, 332-8	2.8	48
134	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 432-470	4.5	46
133	Treatment of two patients with generalized pustular psoriasis with the interleukin-1 $\beta$ inhibitor gevokizumab. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 239-41	4	44
132	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, 61-3	4.5	44
131	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1681-1692	4.6	42
130	Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 88-95	4	42
129	Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 88-101	6.1	41
128	Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. <i>PLoS ONE</i> , <b>2011</b> , 6, e20279	3.7	41
127	Anti-IL17 therapies for psoriasis. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 45-54	5.4	40

126	Phototherapy in dermatology: A call for action. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 1078-80	4.5	39
125	Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes. <i>JAMA Dermatology</i> , <b>2016</b> , 152, 1244-1253	5.1	39
124	Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 634-42	4.6	39
123	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 436-439.e1	4.5	39
122	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 1784-1793.e2	4.3	36
121	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 67, 1349-614.5	4.5	35
120	Psoriatic arthritis: an update. <i>Arthritis</i> , <b>2012</b> , 2012, 176298		35
119	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. <i>Health and Quality of Life Outcomes</i> , <b>2008</b> , 6, 75	3	34
118	Psoriasis in practice. <i>Lancet, The</i> , <b>1991</b> , 338, 231-4	4.0	31
117	Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. <i>Drug Design, Development and Therapy</i> , <b>2018</b> , 12, 3879-3883	4.4	31
116	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. <i>Dermatology and Therapy</i> , <b>2017</b> , 7, 365-381	4	30
115	Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. <i>Journal of Drugs in Dermatology</i> , <b>2013</b> , 12, 92-8	2.2	29
114	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. <i>Biologics: Targets and Therapy</i> , <b>2014</b> , 8, 169-82	4.4	28
113	The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. <i>Molecular Diagnosis and Therapy</i> , <b>2010</b> , 14, 81-93	4.5	28
112	A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 61, S1-S46	4.5	28
111	Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. <i>International Journal of Dermatology</i> , <b>2007</b> , 46, 637-48	1.7	28
110	Long-term management of plaque psoriasis with continuous efalizumab therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S182-8	4.5	28
109	Current investigational drugs in psoriasis. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 473-87	5.9	27

108	Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. <i>Journal of Drugs in Dermatology</i> , <b>2009</b> , 8, 52-7	2.2	27
107	OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 68, 756-64	4.5	26
106	CARD14 alterations in Tunisian patients with psoriasis and further characterization in European cohorts. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 330-7	4	24
105	Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis. <i>Journal of Drugs in Dermatology</i> , <b>2014</b> , 13, 554-62	2.2	20
104	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 863-871	7.1	19
103	Biological therapies for psoriasis. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 1715-30	5.4	19
102	Recognizing and managing comorbidities and complications in hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2014</b> , 33, S54-6	1.4	19
101	Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. <i>Skinmed</i> , <b>2017</b> , 15, 119-124	0.2	19
100	An overview of developing TNF-targeted therapy for the treatment of psoriasis. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1343-54	5.9	18
99	Prevalence of genital psoriasis in patients with psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2018</b> , 29, 754-760	2.8	17
98	Recurrent renal cell carcinoma presenting as skin nodules: two case reports and review of the literature. <i>Cutis</i> , <b>1989</b> , 44, 305-8	0.4	17
97	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , <b>2017</b> , 18, 405-411	7.1	16
96	Emerging topical treatments for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 523-32	3.7	16
95	Rationale for the use of topical corticosteroids in melasma. <i>Journal of Drugs in Dermatology</i> , <b>2004</b> , 3, 169-74	2.2	16
94	Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. <i>Therapeutic Delivery</i> , <b>2017</b> , 8, 737-746	3.8	15
93	Emerging oral drugs for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 209-20	3.7	15
92	The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 1-19	5.1	15
91	Psoriasis and psoriatic arthritis overview. <i>American Journal of Managed Care</i> , <b>2016</b> , 22, s216-24	2.1	13

90	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. <i>Transplant International</i> , <b>2019</b> , 32, 1268-1276	3	12
89	Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. <i>Dermatology and Therapy</i> , <b>2016</b> , 6, 639-647	4	12
88	A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 1337-1344	5.9	12
87	Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. <i>Journal of Drugs in Dermatology</i> , <b>2008</b> , 7, 1137-46	2.2	12
86	Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. <i>Journal of Drugs in Dermatology</i> , <b>2011</b> , 10, 539-44	2.2	12
85	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , <b>2016</b> , 25, 1179-88	3.7	11
84	Palmoplantar pustular psoriasis unresponsive to the interleukin-1 $\beta$ antagonist canakinumab. <i>Clinical and Experimental Dermatology</i> , <b>2016</b> , 41, 324-6	1.8	11
83	Tumour necrosis factor- $\alpha$ inhibitor use in patients with psoriasis with organ transplantation. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 481-3	4	11
82	Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 1037-1048	4	11
81	Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 2126-2133	4.6	10
80	Ustekinumab for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 189-202	5.1	10
79	Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials. <i>Psoriasis Forum</i> , <b>2007</b> , 13a, 21-27		10
78	One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. <i>Cutis</i> , <b>2008</b> , 81, 509-16	0.4	10
77	No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, e105-e107	4	9
76	Emerging therapies for the treatment of psoriasis. <i>Dermatology and Therapy</i> , <b>2012</b> , 2, 16	4	9
75	The Koo-Menter Psoriasis Instrument for Identifying Candidate Patients for Systemic Therapy. <i>Psoriasis Forum</i> , <b>2003</b> , 9a, 6-9		9
74	The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2004</b> , 8 Suppl 2, 20-5	1.6	9
73	Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 519-522	4.5	9



72	Nodular fasciitis of the lip mucosa: a rare but clinically important entity. <i>Clinical and Experimental Dermatology</i> , <b>2015</b> , 40, 408-12	1.8	8
71	Ustekinumab treatment for psoriasis in 119 patients maintained on therapy for a minimum of one year: a review. <i>Journal of Drugs in Dermatology</i> , <b>2014</b> , 13, 905-10	2.2	8
70	Psoriasis and psoriatic arthritis treatment. <i>American Journal of Managed Care</i> , <b>2016</b> , 22, s225-37	2.1	8
69	Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 385-400	4	7
68	Angiolymphoid hyperplasia with eosinophilia. <i>Baylor University Medical Center Proceedings</i> , <b>2014</b> , 27, 336-7	0.6	6
67	Ponesimod--a future oral therapy for psoriasis?. <i>Lancet, The</i> , <b>2014</b> , 384, 2006-8	4.0	6
66	Successful treatment of generalized granuloma annulare with adalimumab. <i>Clinical and Experimental Dermatology</i> , <b>2015</b> , 40, 537-9	1.8	5
65	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 923-930	4.5	5
64	A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , <b>2017</b> , 9, 963-978	3.8	5
63	The prevalence of Dupuytren contractures in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , <b>2014</b> , 39, 894-9	1.8	5
62	Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab		5
61	Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1917-1929	4	5
60	Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor. <i>Journal of Dermatological Treatment</i> , <b>2016</b> , 27, 418-21	2.8	5
59	The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 231-44; quiz 245-6	4.5	4
58	The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 247-70; quiz 271-2	4.5	4
57	Use of pharmacogenomics in psoriasis. <i>Clinical Investigation</i> , <b>2011</b> , 1, 399-411		4
56	Cost-efficacy analysis of biological treatments in psoriasis: an 18-month assessment. <i>Journal of Medical Economics</i> , <b>2005</b> , 8, 139-146	2.4	4
55	Hidradenitis suppurativa: update on diagnosis and treatment. Introduction. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2014</b> , 33, S47	1.4	4

54	Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itch. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 19-20	4	4
53	Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 763-768	2.8	4
52	Pathogenesis and genetics of psoriasis. <i>Cutis</i> , <b>1998</b> , 61, 8-10	0.4	4
51	Psoriasis as the marker of underlying systemic disease. <i>Skin Therapy Letter</i> , <b>2008</b> , 13, 1-5	1.8	4
50	Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). <i>Journal of Medical Economics</i> , <b>2019</b> , 22, 936-944	2.4	3
49	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 544-51	4.5	3
48	OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. <i>Psoriasis Forum</i> , <b>2010</b> , 16a, 3-7		3
47	Quality of life instruments in psoriasis clinical trials. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 563	4	2
46	Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date. <i>Clinical, Cosmetic and Investigational Dermatology</i> , <b>2019</b> , 12, 249-253	2.9	2
45	Reporting of MABp1 for the Treatment of Psoriasis. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1143-4	5.1	2
44	Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 615-621	4	2
43	Diffuse dermal angiomatosis of the breast. <i>Baylor University Medical Center Proceedings</i> , <b>2020</b> , 33, 273-275		2
42	A novel classification system for dysplastic nevus and malignant melanoma <b>2016</b> ,		2
41	Symptomatic hypercalcemia and scarring alopecia as presenting features of sarcoidosis. <i>Baylor University Medical Center Proceedings</i> , <b>2018</b> , 31, 224-226	0.6	2
40	Reply: To PMID 23317980. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 198	4.5	2
39	Polymorphic blistering eruption and stomatitis in a patient with non-Hodgkin lymphoma. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 439-40	5.1	2
38	Secondary syphilis and HIV. <i>Baylor University Medical Center Proceedings</i> , <b>2012</b> , 25, 87-9	0.6	2
37	Goeckerman therapy versus biologics in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 516-7	4.5	2

36	The ethics of consulting with pharmaceutical companies. <i>Clinics in Dermatology</i> , <b>2009</b> , 27, 339-45	3	2
35	Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA B: Post-Hoc Analysis From Three Randomized Controlled Trials. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 1111-1120	4	2
34	Recurrent lumbosacral herpes simplex virus infection. <i>Baylor University Medical Center Proceedings</i> , <b>2016</b> , 29, 48-9	0.6	2
33	Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 1365-9	4	2
32	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e21-e24	4.6	2
31	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 87-96	5.4	2
30	Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. <i>Cutis</i> , <b>2012</b> , 89, 89-94	0.4	2
29	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, e544-e547	4.6	1
28	SAT0561 Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 863.1-863	2.4	1
27	Reply: Genital edema in Crohn's disease. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 385	4.5	1
26	A Quaternary Classifier for the Clinical Evaluation of Pigmented Skin Lesions <b>2020</b> ,		1
25	Topical dermal steroid-induced retinopathy. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 868-870	1.4	1
24	A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 1121-1135	4	1
23	Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14486	2.2	1
22	A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1851-1860	4	1
21	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 2409-2414	4.6	1
20	Adalimumab in paediatric psoriasis. <i>Lancet, The</i> , <b>2017</b> , 390, 5-6	4.0	0
19	The use of tumor necrosis factor inhibitors in pregnancy: what is the evidence?. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 829-31	4.5	0

- 18 Polymorphic plaques involving the face and extremities. *JAMA Dermatology*, **2014**, 150, 643-4 5.1 0
- 17 Ethical dilemma in missed melanoma: What to tell the patient and other providers. *Journal of the American Academy of Dermatology*, **2017**, 76, 365-367 4.5
- 16 A congenital naevus in a blaschkoid distribution. *Clinical and Experimental Dermatology*, **2018**, 43, 216-218 0.6
- 15 Image Gallery: Cutaneous T-cell lymphoma mimicking a gyrate erythema. *British Journal of Dermatology*, **2016**, 174, e42 4
- 14 Complementary data for long-term infliximab use in psoriasis. *Journal of the American Academy of Dermatology*, **2014**, 71, 591 4.5
- 13 Recent and future developments in targeted therapy **2014**, 249-267
- 12 Widespread dermal ulcerations and bullae. *Baylor University Medical Center Proceedings*, **2012**, 25, 155-8 0.6
- 11 Letter from the editors. *Dermatology and Therapy*, **2011**, 1, 1 4
- 10 The International Psoriasis Council Presents Top 10 Psoriasis Research Articles for 2010. *Psoriasis Forum*, **2010**, 16a, 44-51
- 9 Pustules and dystrophy of the nails. *Baylor University Medical Center Proceedings*, **2009**, 22, 162-3 0.6
- 8 The International Psoriasis Council Presents Top 2009 Research Articles. *Psoriasis Forum*, **2009**, 15a, 24-32
- 7 Psoriasis symposium. Topical therapy. *Seminars in Dermatology*, **1992**, 11, 5-10
- 6 Psoriasis symposium. Cyclosporine. *Seminars in Dermatology*, **1992**, 11, 30-4
- 5 What you should know about hidradenitis suppurativa (HS): information for patients. *Seminars in Cutaneous Medicine and Surgery*, **2014**, 33, S60-1 1.4
- 4 Multifactorial Diseases with Immunological Involvement **2017**, 221-258
- 3 AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2. *Annals of the Rheumatic Diseases*, **2021**, 80, 1304.2-1305 2.4
- 2 Penile calciphylaxis with extragenital gangrene. *Baylor University Medical Center Proceedings*, **2021**, 34, 416-418 0.6
- 1 Normocomplementemic urticarial vasculitis in a young female with persistent joint pain. *International Journal of Dermatology*, **2021**, 1.7

